Itraconazole and terbinafine in perspective: From petri dish to patient

Journal of the European Academy of Dermatology and Venereology

Volumn 12, Issue SUPPL., 1999, Pages

  De Doncker, P ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Fungal infections; Itraconazole; Onychomycosis; Terbinafine; Tinea pedis; Treatment

Indexed keywords

ITRACONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; CONFERENCE PAPER; DERMATOPHYTE; HUMAN; MYCOSIS; ONYCHOMYCOSIS; PRIORITY JOURNAL; TINEA PEDIS;

ANIMALS; ANTIFUNGAL AGENTS; CLINICAL TRIALS; FOOT DERMATOSES; HUMANS; ITRACONAZOLE; NAPHTHALENES; ONYCHOMYCOSIS; TINEA PEDIS;

EID: 0032840688     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0926-9959(99)00054-9     Document Type: Conference Paper

References (31)

1. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J. Quality of life in persons with onychomycosis. Qual Life Res 1993;2:341-348.
2. Clayton Y. Relevance of broad spectrum and fungicidal activity of anti-fungals in the treatment of dermatomycosis. Br J Dermatol 1994;130(S43):7-8.
3. Van Cutsem J. An investigation of the in vitro activity of antifungal spectrum of itraconazole and terbinafine in relation to in vivo and other mycoses. J Mycolog Med 1994;4:137-144.
4. Janssen T, Xhonneux B, et al. Borgers. M .. An investigation into the antifungal mechanism of action of itraconazole and terbinafine in experimental trichophytosis. Eur J Dermatol 1993;3:43-49.
5. Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically and parentally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987;9:S15-S32.
6. Piérard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Ac Dermatol 1995;32:429-435.
7. De Doncker P, et al. Antifungal pulse therapy in onychomycosis: a pharmacokinetic/ pharmacodynamic investigation of monthly cycles of 1-week pulse with itraconazole. Arch Dermatol 1996;132:34-41.
8. De Doncker, P., Van Cutsem, J., Piérard, G., Gupta, A.K., Marynissen, G., Del Rosso, J.Q., Itraconazole compared to terbinafine in superficial fungal infections: from petri dish to patient! Poster, AAD, Orlando.
9. De Doncker, P., et al., Safety and efficacy of oral antifungal agents: focus on itraconazole pulse. Poster, AAD, Chicago.
10. Degreef H. Del Palacio. A., Myginol, S., Ginter, G., Soares, AP, Zuluaga, De Cadena, A., Randomized double-blind comparison of short-term itraconazole and terbinafine therap for toenail onychomycosis. Acta Dermatologica Veneor 1998;.
11. Arenas R, Dominguez-Cherit J, Fernandez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995;34:138-143.
12. Kedja, J., An open randomized study comparing itraconazole pulse therapy with terbinafine continuous dosing for the treatment of toenail onychomycosis. Annual meeting AAD, New Orleans, 1999.
13. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. Pharmacoeconomics 1998(Feb);13(2):243-256.
14. De Doncker, P., Gupta, A.K., Del Rosso, J.Q., Daniel, C.R., Rosen, T., Verspeelt, J., et al., Update on the safety of itraconazole pulse therapy in onychomycosis. Safety poster, AAD, Orlando, 1999.
15. Gupta AK, De Doncker P, Scher R, Haneke E, Daniel RC, André J, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998;37:303-308.
16. Bailar III JC. The practice of meta-analysis. J Clin Epdiemiol 1995;48:149-157.
17. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993;341:418-422.
18. Leloriere J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. New Engl J Med 1997;337(8):536-542.
19. Marchetti A, Piech CT, McGhan WF, et al. Pharmaconomic analysis of oral therapies: a US model. Clin Ther 1996;18(4):757-777.
20. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials 1986;1:177-178.
21. Velanovich V. Meta-analysis for combining Bayesian probabilities. Med Hypotheses 1 1991;35:192-195.
22. Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmaconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994;130(Suppl. 43):35-44.
23. Van Doorslaer EKA, Tormans G, Gupta AK, et al. Economic evluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dematology 1996;193:239-244.
24. Evans EGV, Sigurgeirsson B. Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Br Med J 1999;318:1031-1035.
25. Negroni R, Arechavala A, Bonvehi P. Onychomycosis due to mycelial fungi, a private clinical experience in Argentina. Revista Argentina de Micologia 1998;21:8-14.
26. Bahandir S, Sethat-Insloz H, Aganglu C, et al. Continuous Terbinafine or pulse Itraconazole: a comparative study on onychomycosis. J Dermatol Treat 1998;9:271.
27. Kejda, J., An Open, Randomized Study Comparing Itraconazole Pulse Therapy with Terbinafine Continuous Dosing for the Treatment of Toenail Onychomycosis. American Academy of Dermatology Scientific Poster Session. March 19-23, 1999, New Orleans, Louisiana, USA.
28. Product monograph of terbinafine.
29. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine. Arch Dermatol 1997;133:1213-1219.
30. Amichai B, Grunwald M. Adverse drug reactions of the new oral antifungal agents - terbinafine, fluconazole and itraconazole. Int J Dermatol 1998;37:410-415.
31. Nolting SK. Sanchez Carazo, . J. De Boulle, K., Lambert, J.R., Oral treatment schedules for onychomycosis: a study of patient preference. Int J Dermatol 1998;37:454-456.